Effective Reduction of Post-inflammatory Hyperpigmentation with the Tyrosinase Inhibitor Isobutylamido-thiazolyl-resorcinol (Thiamidol)

Overview

Journal Int J Cosmet Sci

Specialty Dermatology

Date 2021 Feb 9

PMID 33559186

Citations 9

Authors

Dennis Roggenkamp

Ncoza Dlova

Tobias Mann

Jan Batzer

Julia Riedel

Martina Kausch

Ivica Zoric

Ludger Kolbe

Affiliations

Soon will be listed here.

Abstract

Objective: Post-inflammatory hyperpigmentation (PIH) is a major cosmetic concern especially in individuals with darker skin complexion. Unfortunately, treatment with anti-inflammatory ingredients alone does not prevent the development of hyperpigmented spots. Recently, isobutylamido-thiazolyl-resorcinol (Thiamidol) was described as a very potent inhibitor of human tyrosinase. The objective of this research was to investigate the potential of this compound to prevent PIH induced by epidermal wounding (suction blister) and related to acne.

Methods: Suction blister-induced PIH was treated with a formulation containing Thiamidol or a vehicle for 3 months, and the changes in hyperpigmentation were monitored by spectroscopic measurements. The effect of skin care formulations containing Thiamidol on acne-related PIH was investigated in two studies, a vehicle-controlled, double-blinded, randomized clinical study and a clinical observational study. Both studies had a duration of 3 months and included assessments such as clinical photography, clinical grading and melanin index measurements.

Results: Already after 2 weeks of treatment, suction blister sites treated with Thiamidol were significantly lighter than control sites and improved throughout the treatment period. Subjects´ self-grading demonstrated that Thiamidol significantly improved the visibility of acne-induced hyperpigmentation compared to the vehicle treatment. A skin care regimen with Thiamidol significantly improved acne-related PIH over 12 weeks shown by Mexameter measurements, expert grading, self-grading and clinical photography.

Conclusion: Thiamidol represents a safe and effective ingredient for cosmetic products against post-inflammatory hyperpigmentation.

Citing Articles

Tyrosinase Inhibition and Antimelanogenic Effects of Resorcinol-Containing Compounds.

Beaumet M, Lazinski L, Maresca M, Haudecoeur R ChemMedChem. 2024; 19(23):e202400314.

PMID: 39105380 PMC: 11617669. DOI: 10.1002/cmdc.202400314.

Treatment of Post-Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review.

Mar K, Khalid B, Maazi M, Ahmed R, Wang O, Khosravi-Hafshejani T J Cutan Med Surg. 2024; 28(5):473-480.

PMID: 39075672 PMC: 11514325. DOI: 10.1177/12034754241265716.

Exploring the potential of white birch sap: A natural alternative to traditional skin whitening agents with reduced side effects.

Liu F, Xu T, He J, Jiang Y, Qu L, Wang L Heliyon. 2024; 10(5):e26715.

PMID: 38455547 PMC: 10918162. DOI: 10.1016/j.heliyon.2024.e26715.

Acne treatment challenges - Recommendations of Latin American expert consensus.

Rocha M, Barnes F, Calderon J, Fierro-Arias L, Gomez C, Munoz C An Bras Dermatol. 2024; 99(3):414-424.

PMID: 38402012 PMC: 11074621. DOI: 10.1016/j.abd.2023.09.001.

Tetrahedral framework nucleic acid loaded with glabridin: A transdermal delivery system applicated to anti-hyperpigmentation.

He J, Chen W, Chen X, Xie Y, Zhao Y, Tian T Cell Prolif. 2023; 56(12):e13495.

PMID: 37132449 PMC: 10693180. DOI: 10.1111/cpr.13495.

References

Grimes P . Management of hyperpigmentation in darker racial ethnic groups. Semin Cutan Med Surg. 2009; 28(2):77-85. DOI: 10.1016/j.sder.2009.04.001. View

Simmons B, Griffith R, Bray F, Falto-Aizpurua L, Nouri K . Exogenous ochronosis: a comprehensive review of the diagnosis, epidemiology, causes, and treatments. Am J Clin Dermatol. 2015; 16(3):205-12. DOI: 10.1007/s40257-015-0126-8. View

Espin J, Varon R, Fenoll L, Gilabert M, Garcia-Ruiz P, Tudela J . Kinetic characterization of the substrate specificity and mechanism of mushroom tyrosinase. Eur J Biochem. 2000; 267(5):1270-9. DOI: 10.1046/j.1432-1327.2000.01013.x. View

Callender V, F Alexis A, Daniels S, Kawata A, Burk C, Wilcox T . Racial differences in clinical characteristics, perceptions and behaviors, and psychosocial impact of adult female acne. J Clin Aesthet Dermatol. 2014; 7(7):19-31. PMC: 4106354. View

Sudel K, Venzke K, Knussmann-Hartig E, Moll I, Stab F, Wenck H . Tight control of matrix metalloproteinase-1 activity in human skin. Photochem Photobiol. 2003; 78(4):355-60. DOI: 10.1562/0031-8655(2003)078<0355:tcomma>2.0.co;2. View

Taylor S, Grimes P, Lim J, Im S, Lui H . Postinflammatory hyperpigmentation. J Cutan Med Surg. 2009; 13(4):183-91. DOI: 10.2310/7750.2009.08077. View

Cordes P, Sun W, Wolber R, Kolbe L, Klebe G, Rohm K . Expression in non-melanogenic systems and purification of soluble variants of human tyrosinase. Biol Chem. 2012; 394(5):685-93. DOI: 10.1515/hsz-2012-0300. View

Callender V, St Surin-Lord S, Davis E, Maclin M . Postinflammatory hyperpigmentation: etiologic and therapeutic considerations. Am J Clin Dermatol. 2011; 12(2):87-99. DOI: 10.2165/11536930-000000000-00000. View

Mishra S, Dhurat R, Deshpande D, Nayak C . Diagnostic utility of dermatoscopy in hydroquinone-induced exogenous ochronosis. Int J Dermatol. 2012; 52(4):413-7. DOI: 10.1111/j.1365-4632.2011.05305.x. View

10.

Arrowitz C, Schoelermann A, Mann T, Jiang L, Weber T, Kolbe L . Effective Tyrosinase Inhibition by Thiamidol Results in Significant Improvement of Mild to Moderate Melasma. J Invest Dermatol. 2019; 139(8):1691-1698.e6. DOI: 10.1016/j.jid.2019.02.013. View

11.

Cestari T, Dantas L, Boza J . Acquired hyperpigmentations. An Bras Dermatol. 2014; 89(1):11-25. PMC: 3938350. DOI: 10.1590/abd1806-4841.20142353. View

12.

Kiistala U . Suction blister device for separation of viable epidermis from dermis. J Invest Dermatol. 1968; 50(2):129-37. DOI: 10.1038/jid.1968.15. View

13.

Hearing Jr V, EKEL T, Montague P, Nicholson J . Mammalin tyrosinase. Stoichiometry and measurement of reaction products. Biochim Biophys Acta. 1980; 611(2):251-68. DOI: 10.1016/0005-2744(80)90061-3. View

14.

Mann T, Scherner C, Rohm K, Kolbe L . Structure-Activity Relationships of Thiazolyl Resorcinols, Potent and Selective Inhibitors of Human Tyrosinase. Int J Mol Sci. 2018; 19(3). PMC: 5877551. DOI: 10.3390/ijms19030690. View

15.

Garcia-Molina F, Hiner A, Fenoll L, Rodriguez-Lopez J, Garcia-Ruiz P, Garcia-Canovas F . Mushroom tyrosinase: catalase activity, inhibition, and suicide inactivation. J Agric Food Chem. 2005; 53(9):3702-9. DOI: 10.1021/jf048340h. View

16.

Westerhof W, Kooyers T . Hydroquinone and its analogues in dermatology - a potential health risk. J Cosmet Dermatol. 2006; 4(2):55-9. DOI: 10.1111/j.1473-2165.2005.40202.x. View

17.

Mann T, Gerwat W, Batzer J, Eggers K, Scherner C, Wenck H . Inhibition of Human Tyrosinase Requires Molecular Motifs Distinctively Different from Mushroom Tyrosinase. J Invest Dermatol. 2018; 138(7):1601-1608. DOI: 10.1016/j.jid.2018.01.019. View

18.

Del Bino S, Duval C, Bernerd F . Clinical and Biological Characterization of Skin Pigmentation Diversity and Its Consequences on UV Impact. Int J Mol Sci. 2018; 19(9). PMC: 6163216. DOI: 10.3390/ijms19092668. View

19.

Abad-Casintahan F, Chow S, Goh C, Kubba R, Hayashi N, Noppakun N . Frequency and characteristics of acne-related post-inflammatory hyperpigmentation. J Dermatol. 2016; 43(7):826-8. DOI: 10.1111/1346-8138.13263. View

20.

Davis E, Callender V . Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010; 3(7):20-31. PMC: 2921758. View